LNIT-Local nasal immunotherapy in allergic rhinitis: Revisited evidence and perspectives
Issued Date
2022-08-01
Resource Type
ISSN
15284050
eISSN
14736322
Scopus ID
2-s2.0-85134721459
Pubmed ID
35779069
Journal Title
Current Opinion in Allergy and Clinical Immunology
Volume
22
Issue
4
Start Page
259
End Page
267
Rights Holder(s)
SCOPUS
Bibliographic Citation
Current Opinion in Allergy and Clinical Immunology Vol.22 No.4 (2022) , 259-267
Suggested Citation
Kanjanawasee D., Tantilipikorn P. LNIT-Local nasal immunotherapy in allergic rhinitis: Revisited evidence and perspectives. Current Opinion in Allergy and Clinical Immunology Vol.22 No.4 (2022) , 259-267. 267. doi:10.1097/ACI.0000000000000830 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/85672
Title
LNIT-Local nasal immunotherapy in allergic rhinitis: Revisited evidence and perspectives
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Purpose of reviewAllergen immunotherapy (AIT) is a personalized treatment approach for the allergic airway disease. The most common routes of administration are subcutaneous and sublingual. Local nasal immunotherapy (LNIT) presents another alternative route for allergen desensitization. Nasal mucosa is the first entry site of pathogens and numerous lymphoid organs are located in this area, making LNIT a favorable method for triggering immune tolerance. LNIT has shown promising results in reducing symptoms and medication use in allergic rhinitis patients. Over time, difficulties in dosing adjustments have made this method less popular. Recent advances in intranasal drug delivery systems warrant re-examination of LNIT as a viable option for the treatment of the allergic airway disease.Recent findingsThe scope of the review includes evidences of LNIT in human trials including comparison with placebo and conventional method of immunotherapy. Recent articles regarding the mechanism of LNIT and the challenges of intranasal drug delivery are reviewed. Advances in the LNIT delivery system which have overcome previous limitations demonstrate promising effects.SummaryLNIT presents a judicious alternative for noninjection AIT. The evidences from previous clinical trials and the novel improvement of drug delivery system will lead into the future allergen vaccine production.